Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01493154 · ClinicalTrials.gov registry record · Phase 1
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01493154 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 2 participants.
The verdict
NCT01493154, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated cancer cells. In addition to giving the vaccine using an electroporation device, we are giving the vaccine in combination with an immunomodulatory agent to further enhance immune responses against HPV-infected and associated cancer cells.
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL DNA Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01493154
The ClinicalTrials.gov registry entry for NCT01493154 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT01493154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01493154 about?
NCT01493154 is a clinical study titled "Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients". This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated c...
What is the current status of trial NCT01493154?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2012-04. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01493154?
The interventions under investigation include: Cyclophosphamide (DRUG), DNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01493154?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.